Related Experiment Videos
Homocysteine as a risk factor for restenosis after coronary angioplasty
H Morita1, H Kurihara, T Kuwaki
1Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Japan. hmrt-tky@umin.ac.jp
Insights
Elevated plasma homocysteine levels are linked to restenosis after percutaneous transluminal coronary angioplasty (PTCA). This suggests homocysteine may predict restenosis, offering a target for prevention strategies.
Area of Science:
- Cardiovascular Medicine
- Clinical Chemistry
Background:
- Restenosis remains a significant complication following percutaneous transluminal coronary angioplasty (PTCA).
- Identifying predictors of restenosis is crucial for improving patient outcomes.
Purpose of the Study:
- To investigate the association between plasma homocysteine levels and the occurrence of restenosis after successful PTCA.
- To determine if plasma homocysteine can serve as a predictive marker for restenosis.
Main Methods:
- A cohort of 112 male patients undergoing elective PTCA were enrolled.
- Plasma homocysteine levels were measured at follow-up angiography.
- Patients were categorized into restenosis and non-restenosis groups for comparison.
Main Results:
- Patients with restenosis exhibited significantly higher plasma homocysteine levels compared to those without restenosis (15.0 +/- 3.9 vs. 13 +/- 2.9 micromol/L; P = 0.011).
- This association was more pronounced in diabetic patients.
- A threshold effect of hyperhomocysteinemia was observed between the groups.
Conclusions:
- Plasma homocysteine is a potential risk factor for restenosis after PTCA.
- Therapeutic interventions targeting hyperhomocysteinemia may help prevent restenosis.
Abstract:
We examined the relationship between plasma homocysteine levels and restenosis after PTCA (Percutaneous transluminal coronary angioplasty) to investigate whether plasma homocysteine levels can be a predictor of restenosis after PTCA. One hundred and twelve male patients who have undergone a successful elective PTCA were consecutively enrolled and plasma homocysteine levels were measured at the time of follow-up angiography. Plasma homocysteine levels in patients with restenosis were significantly higher than those in patients without restenosis (15.0 +/- 3.9 vs. 13 +/- 2.9 micromol/L; P = 0.011). The difference was augmented when diabetic patients were selectively studied. The comparison between restenosis group and non-restenosis group indicated the threshold effect of hyperhomocysteinemia. These results suggest that plasma homocysteine is a potential risk factor of restenosis after PTCA, and therapeutic strategy targeted against hyperhomocysteinemia may be beneficial for preventing restenosis.